Patrina buys OVAS 10.25: Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs.

Finally, HC Wainwright set a $100.00 target price on shares of OvaScience and gave the company a buy rating in a research note on Saturday, June 20th. They set a neutral rating and a $40.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of OvaScience in a research report on Monday, June 29th. Wedbush reiterated a buy rating and issued a $46.00 price objective (down from $52.00) on shares of OvaScience in a report on Tuesday, August 11th. OvaScience ( NASDAQ:OVAS ) traded up 3.13% on Friday, hitting $23.72. The stock had a trading volume of 227,067 shares.


Lavenia:
JPMorgan Chase & Co. began coverage on OvaScience in a report on Monday, June 29th.

Tillie:
Oppenheimer set a $60.00 target price on shares of OvaScience and gave the stock a buy rating in a report on Saturday, June 20th.

Leisa:
OVAS has been the subject of several other reports.

Shawna:
The company reported ($0.64) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.64). On average, analysts predict that OvaScience will post ($2.52) EPS for the current year.

Denice:
Oppenheimer set a $60.00 price objective on shares of OvaScience and gave the company a buy rating in a research report on Saturday, June 20th.

Debbi:
OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.

Nicki:
OvaPrime treatment is a potential fertility treatment that could enable a woman to expand her egg reserve.

Hannah:
The AUGMENT treatment complements the standard of practice for an IVF cycle.

Janie:
JPMorgan Chase & Co. started coverage on shares of OvaScience in a research note on Monday, June 29th.

Shanta:
OvaScience ( NASDAQ:OVAS ) opened at 26.04 on Tuesday.

Ovascience (NASDAQ:OVAS)
//stockhand.net/us/?q=nasdaq%3Aovas&id=256731